麗人麗粧(605136.SH):麗人管理擬受讓新餘元創所持蘇州元創進取2000萬元基金份額
格隆匯5月10日丨麗人麗粧(605136.SH)公佈,公司全資子公司上海麗人麗粧企業管理有限公司(以下簡稱“麗人管理”)擬受讓蘇州元創進取創業投資中心(有限合夥)(以下簡稱“蘇州元創進取”或“合夥企業”)基金中的有限合夥人新餘元創灝創投資管理合夥企業(有限合夥)(以下簡稱“新餘元創”)的份額。
蘇州元創進取募集規模為人民幣5.11億元。新餘元創於2020年6月向其認繳出資人民幣4.35億元。現麗人管理擬受讓其中2000萬元對應的基金份額,受讓金額為人民幣2000萬元,資金來源為公司自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.